Relevant bibliographies by topics / CD20 antibodies

Academic literature on the topic 'CD20 antibodies'

Author: Grafiati
Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'CD20 antibodies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "CD20 antibodies"

1

Fuh, Franklin, Reina Fuji, Kirsten A. Poon, Dongwei Li, Clarissa David, Quyen Nguyen, Kathy Howell, et al. "Pharmacodynamic Effects of Administration of Maytansine Conjugated Anti-CD22 Monoclonal Antibodies to Cynomolgus Monkeys." Blood 112, no. 11 (November 16, 2008): 4996. http://dx.doi.org/10.1182/blood.v112.11.4996.4996.

Full text
Abstract:
Abstract CD22 is a B cell-specific glycoprotein expressed on the cell surface of all mature B cells. A candidate therapeutic anti-CD22 antibody, 10F4v3, was conjugated to the anti-mitotic agent maytansine (10F4v3-DM1). DM1 disrupts cellular mitosis through inhibition of tubulin polymerization when internalized into cells. The anti-CD22 DM1 conjugate was shown to have significant potency in preclinical efficacy models of NHL. In order to further characterize this antibody-drug conjugate in preclinical studies, we first evaluated the binding characteristics of the 10F4v3 to peripheral blood B cells from various geographical sources of cynomolgus monkeys. 10F4v3 bound to peripheral blood B cells from all cynomolgus monkeys of Indonesian and Mauritian origins, but displayed only limited binding to cynomolgus monkeys of Chinese and Cambodian origins. Therefore, further pre-clinical evaluation of 10F4v3-DM1 was conducted in Indonesian cynomolgus monkeys to examine the safety, pharmacokinetic, and pharmacodynamic effects in monkeys dosed at 10, 20, and 30 mg/kg (2000, 4000, and 6000 mg/m2 DM1). Pharmacodynamic assessments of peripheral blood and lymphoid tissues included examination of B cells, B cell subsets, CD4+ T cells, CD8+ T cells, and CD3−CD20− (NK) cells. B cell subsets included CD20+, CD20+CD21+, CD20+CD21−, CD20+CD21+CD27+, CD20+CD21+CD27−, and CD20+CD21high lymphocytes which are phenotypically similar to human B cells, mature B cells, germinal center B cells, memory B cells, naïve B cells, and marginal zone B cells, respectively. B cells and B cell subsets were substantially depleted in peripheral blood at all doses, with no apparent dose-dependent effects. In lymphoid tissue, B cells were also depleted, with substantial depletion of CD20+CD21− and CD20+CD21high B cell subsets in spleen and bone marrow. Based on the nonclinical data, 10F4v3-DM1 exhibits an encouraging pharmacodynamic profile that supports clinical development for the potential treatment of non-Hodgkin’s lymphoma.
APA, Harvard, Vancouver, ISO, and other styles
2

Duperray, C., J. M. Boiron, C. Boucheix, J. F. Cantaloube, T. Lavabre-Bertrand, M. Attal, J. Brochier, D. Maraninchi, R. Bataille, and B. Klein. "The CD24 antigen discriminates between pre-B and B cells in human bone marrow." Journal of Immunology 145, no. 11 (December 1, 1990): 3678–83. http://dx.doi.org/10.4049/jimmunol.145.11.3678.

Full text
Abstract:
Abstract When bone marrow (BM) lymphoid cells from 12 adult healthy donors were labeled by CD24 antibodies and analyzed by flow cytometry, two positive populations of cells were demonstrated in each sample (by a separated bimodal specific immunofluorescence). One population had intermediate CD24-Ag density (termed CD24+ cells) whereas the other had high CD24-Ag density (termed CD24(2+) cells). CD24+ cells represented 5.8 +/- 2.7% of the total lymphoid BM cells and CD24(2+) cells 5.6 +/- 2.5%. Using dual fluorescence analysis on eight samples, all CD24+ cells expressed the CD21 and CD37 mature B cell Ag and also surface IgM (sIgM), but this population lacked CD10 Ag. These cells also expressed CD19 Ag, and at a higher density than CD24(2+) cells. They were also positive for HLA-DR Ag. Conversely, CD24(2+) cells were shown to be early cells of the B cell lineage. While all the CD24(2+) cells were HLA-DR+ and CD19+, 64 +/- 16% of them expressed CD20 Ag (at a lower density than CD24+ cells), 65 +/- 21% CD10 Ag, and 22 +/- 8% were positive for cytoplasmic mu-chains (c mu). None of these cells expressed the CD21 and CD37 mature B cell Ag or sIgM. Additional experiments on four different healthy donors demonstrated that 30 +/- 9% of the CD24(2+) cells expressed the CD34 Ag and that the CD24+ cells did not express it. Thus, the CD24 Ag permits discrimination between two populations of the B cell lineage present in adult BM: 1) A CD24(2+) cell population including "pre" pre-B cells (HLA-DR+, CD19+, CD10+/-, CD20-, CD21-, CD34+, CD37-, c mu-), "intermediate" pre-B cells (HLA-DR+, CD19+, CD10+, CD20+, CD21-, CD34-, CD37-, c mu-), and "true" pre-B cells (HLA-DR+, CD19+, CD10+, CD20+, CD21-, CD34-, CD37-, c mu+). 2) A CD24+ cell population including B cells of the standard phenotype (HLA-DR+, CD19+, CD10-, CD20+, CD21+, CD34-, CD37+, c mu-, sIgM+).
APA, Harvard, Vancouver, ISO, and other styles
3

Rymkiewicz, Grzegorz, Renata Woroniecka, Katarzyna Blachnio, Barbara Pienkowska-Grela, and Jan Walewski. "Flow Cytometry and Fluorescence In Situ Hybridization Are Methods of Choice for Routine Diagnosis of Mantle Cell Lymphoma." Blood 106, no. 11 (November 16, 2005): 4659. http://dx.doi.org/10.1182/blood.v106.11.4659.4659.

Full text
Abstract:
Abstract Mantle cell lymphoma (MCL) is a distinct clinicopathologic entity, characterized by expansion of lymphocytes with co-expression of CD5 and CD20 and frequent t(11;14) translocation. MCL and its morphological variants are frequently confused with other lymphoma subtypes. The aim of this study was to analyze a contribution of histopathology (HP), immunohistochemistry (IHC), flow cytometry (FCM) and cytogenetic analysis with fluorescence in situ hybridization (FISH) to ultimate diagnosis of MCL. We identified 66 pts diagnosed with MCL either by use of HP/IHC or/and FCM. Initial diagnosis was based on HP/IHC only, and was validated in 55 of 66 patients by combined use of HP/IH, FCM, and FISH. We examined paraffin sections IHC panel consisting of antibodies to CD3, CD5, CD20, CD23, CD43, and cyclin D1. FCM analysis was done by 3-colour direct immunofluorescence with extended panel of antibodies to CD5, CD10, CD11c, CD19, CD20, CD22, CD23, CD25, CD38, CD45, HLADR, FMC7, light and heavy chains. We used FISH to detect the t(11;14) in interphase cells of 24 cases of MCL. All 55 cases of MCL were CD20 positive and CD23 negative on IHC, 32 of 51 (63%) and 46 of 52 (88%) cases coexpressed the CD5 and CD43 antigens, respectively. Cyclin-D1 staining revealed nuclear positivity in 38 of 52 (73%) pts. Dual expression of CD5 and cyclin D1 - a finding highly reliable for MCL diagnosis on IHC, was seen in 49% (27/55) of pts. All MCL cases were CD20 (51/51) and CD19 (55/55) positive by FCM with higher intensity of CD20 expression compared to CD19 in 100% (51/51) of cases. CD5 and CD25 were coexpressed in 54 of 55 (98%) and in 43 of 49 (88%) pts respectively. CD22 (45/45) and HLADR (55/55) were positive in all cases. FMC7 and CD38 were found in 22 of 23 (96%) and in 19 of 23 (83%) patients, respectively. CD10, CD11c, CD23 were only seen on a subpopulation of cells with weak intensity in 15%(7/48), 13% (6/45), and 11% (5/46) pts., respectively. MCL cells expressed moderate intensity monoclonal surface light chains in 47 of 52 (90%) pts with L light chain predominance and IgM+/IgD+ in 16 of 17 (94%) pts. False or incomplete initial diagnosis based mainly on lymph node HP/IHC was found in 35 of 66 (53%) cases. False FCM diagnosis of MCL was found in 2 of 66 (3%) cases. Results of FCM and FISH were consistent with the MCL diagnosis in 92% (22/24) of patients, in our hands. Our data indicate that the phenotypic pattern of MCL by FCM is remarkably constant among patients. As MCL represents a frequent diagnostic challenge, a combined use of FCM and FISH may provide an optimum solution.
APA, Harvard, Vancouver, ISO, and other styles
4

Lones, Mark, and Ivan Kirov. "Cell Surface Targets for Monoclonal Antibody Therapy in Lymphoid Neoplasms of Children and Adolescents." Blood 104, no. 11 (November 16, 2004): 4544. http://dx.doi.org/10.1182/blood.v104.11.4544.4544.

Full text
Abstract:
Abstract Recently, monoclonal antibodies have become available for treatment of lymphoid neoplasms in adults, but have not been studied in children and adolescents. These monoclonal antibodies are directed against cell surface antigens CD20 (Rituximab, Ibritumomab-Tiuxetan, Tositumomab), CD22 (Epratuzumab), CD52 (CAMPATH-1H), HLA-DR Beta-chain (Hu1D10), CD23 (IDEC-152), and CD33 (Gemtuzumab Ozogamicin). The objective of this study is to identify cell surface targets eligible for monoclonal antibody therapy in lymphoid neoplasms of children and adolescents. This is a retrospective analysis of lymphoid neoplasms evaluated by flow cytometry immunophenotyping at a single institution from January 2002 to July 2004. All patients were less than 21 years old at primary diagnosis. Flow cytometry immunophenotyping employed a 3-color method. Fluorochrome-conjugated monoclonal antibodies were utilized to detect cell surface antigens: CD20, CD22, CD23 (Becton-Dickinson), and CD52 (CALTAG) conjugated with PE; HLA-DR and CD33 (Becton-Dickinson) conjugated with FITC. For this study, a cell surface antigen was interpreted as positive when neoplastic cells exhibited moderate or bright intensity staining, or interpreted as negative when staining was dim or absent. A total of 95 patients are included in this study. Demographic data: Age <1 to 20 years (median 7); Male=52, Female=43. Diagnoses included: Precursor-B Acute Lymphoblastic Leukemia (Pre-B ALL) = 80, Precursor-T Acute Lymphoblastic Leukemia or Precursor-T Lymphoblastic Lymphoma (Pre-T ALL/LBL) = 11, Burkitt Lymphoma = 4. Total specimens = 105 (primary diagnosis = 82, relapse = 23). Immunophenotyping results for the number of specimens tested are in the Table. Table 1 Diagnosis CD20 CD22 CD52 HLA-DR CD23 CD33 Pre-B ALL 32/86 (37%) 90/90 (100%) 53/57 (93%) 87/87 (100%) 0/15 (0%) 4/90 (4%) Pre-T ALL/LBL 0/11 (0%) 0/11 (0%) 9/10 (90%) 2/11 (18%) 0/5 (0%) 0/11 (0%) Burkitt Lymphoma 4/4 (100%) 4/4 (100%) 3/3 (100%) 3/3 (100%) 0/2 (0%) 0/3 (0%) CD22 was positive (usually bright intensity) in all Pre-B ALL and Burkitt Lymphoma specimens. CD20 was positive in all Burkitt Lymphoma (bright intensity) and in a subset of Pre-B ALL (usually moderate intensity) specimens. CD22 and CD20 were negative in Pre-T ALL/LBL specimens. In a subset, CD52 was positive (moderate to bright intensity) in nearly all specimens. HLA-DR was positive (moderate to bright intensity) in all Pre-B ALL and Burkitt Lymphoma specimens. In a subset, CD23 was negative in all specimens. Also, CD33 was negative in nearly all specimens. In conclusion, lymphoid neoplasms in children and adolescents have cell surface antigens that are eligible targets for currently available monoclonal antibody therapy. Patients with Pre-B ALL are candidates for therapy directed to CD22, CD52, HLA-DR, and a subset to CD20, but not to CD23 or CD33. Patients with Burkitt Lymphoma are eligible for therapy to CD20, CD22, CD52, and HLA-DR, but not CD23 or CD33. Patients with Pre-T ALL/LBL are eligible for therapy to CD52, but not CD20, CD22, HLA-DR, CD23 or CD33. These results indicate that future clinical therapeutic trials can be designed for children and adolescents with lymphoid neoplasms to evaluate monoclonal antibody therapy directed to CD20, CD22, CD52, or HLA-DR, employing single or multiple antibodies as a new modality, in addition to chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
5

Paiva, Aldair Sousa, Alessandra Suelen Jardim Silva, Victor lima Soares, Gustavo Henrique de Medeiros Oliveira, Lenilton Silva DA Silva Júnior, Hugo Henrique de Freitas Ferreira, Rodrigo Villar Freitas, et al. "Importance of Flow Cytometry in the Differential Diagnosis of Hairy Cell Leukemia in the State of Rio Grande Do Norte, Brazil." Blood 136, Supplement 1 (November 5, 2020): 14–15. http://dx.doi.org/10.1182/blood-2020-143225.

Full text
Abstract:
Introduction:Hairy Cell Leukemia (HCL) is a B-cell non-Hodgkin's Lymphoma (B-NHL) representing about 2% of chronic leukemias, is manifested in adults with an average age of 55 years old or more and the ratio of male: female is 5:1, being more common among white people. It is characterized by the presence of neoplastic lymphocytes with cytoplasmic projections (villous cells), a characteristic commonly observed in other DLPCs such as variant HCL (HCL-v) and splenic villous cell lymphoma (SVCL), being the immunophenotyping by flow cytometry determinant in the differential diagnosis of these neoplasms. HCL is characterized by splenomegaly, hepatomegaly, pancytopenia in peripheral blood (PB) with leukopenia, anemia, neutropenia, monocytopenia, and thrombocytopenia. It has a low number of circulating tumor cells, spleen, liver, and bone marrow (BM) infiltration.Objective:To investigate, by flow cytometry, patients with lymphocytosis and presence of villous lymphocytes in the characterization of HCL and HCV-v and SMZL.Methodology:Were investigated samples of peripheral blood (SP) and bone marrow (MO) from 27 patients previously diagnosed with DLPC and presence of villous lymphocytes which were by flow cytometry with a panel of monoclonal antibodies (MoAb) conjugated to fluorochromes and targeted to T-lymphocytes: CD1a, CD2, CD3, CD5, CD7, subpopulation T-helper (CD3/CD4) and T-cytotoxic (CD3/CD8), in addition to TCR a/b and TCR g/d; Natural Killer cells: CD16-56; B-lymphocytes: CD19, CD20, CD21, CD22, CD23, CD79b, CD200, IgM, IgG, IgD, anti-kappa and anti-lambda, in addition to CD10, TdT (Terminal deoxynucleotidyl Transferase), CD103, CD123, CD11c, CD25, CD38, CD138, CD45 and CD14. At the same time, a complete blood count with differential white blood cell count and investigation of clinical and demographic data such as age, sex and ethnicity / race were also performed.Results:The distribution of patients according to ethnicity and gender, there was a predominance of white individuals and males. The age group most affected was in patients older than 60 years. All patients expressed pan-B antigens on leukemic cells with expression of CD19, CD22 / CD20 (Forte), sIgH, associated with clonal restriction for immunoglobulin light chain (kappa= 20 and lambda= 7), associated with FMC7 expression, HLADR, CD38 and CD45 strong and negativity to CD10, CD138, CD200, CD23, CD5, TdT and related T antigens. Sixteen cases were categorized as HCL, six HCLv and five SVCL. The immunophenotyping of HCL cases was positive for CD103, CD25, CD123 and CD11c. HCLv was negative for CD103 in three cases and CD25 and SVCL negative for CD103, CD123 and CD11c and CD25 in all cases.Conclusions:The precise diagnosis of HCL has fundamental importance because each NHL-B has a specific treatment, besides emphasizing the sensitivity and speed of the IFC regarding diagnosis and follow-up. Disclosures No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
6

Geisler, CH, JK Larsen, NE Hansen, MM Hansen, BE Christensen, B. Lund, H. Nielsen, T. Plesner, K. Thorling, and E. Andersen. "Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia." Blood 78, no. 7 (October 1, 1991): 1795–802. http://dx.doi.org/10.1182/blood.v78.7.1795.1795.

Full text
Abstract:
Abstract Blood mononuclear cells from 540 newly diagnosed, unselected patients with B-cell chronic lymphocytic leukemia (CLL) were examined by immunofluorescence flow cytometry for a panel of surface membrane markers, including IgM and IgD, the monoclonal antibodies anti-CD3, -5, -20, -21, -22, -FMC7, and, for the final 125 patients, anti-CD23. There were 503 CD5+ and 37 CD5- cases. In the CD5+ cases, the cells typically expressed IgM, IgD, CD20, CD21, CD22, and CD23. In univariate analysis, age, clinical stage, IgM-fluorescence intensity, CD23, and FMC7 had significant prognostic importance, with high IgM-fluorescence intensity, high FMC7, and low CD23 expression being associated with a short survival. There was no significant difference in survival between 351 cases expressing IgMD and 55 cases expressing IgM without IgD, or between kappa and lambda light chain monoclonal cases. CD20, CD21, and CD22 had no prognostic importance. In Cox multiple regression analyses, age, CD23, IgM-fluorescence intensity, and clinical stage (International Workshop System) had independent prognostic importance. Thus, besides clinical variables, CD23 and IgM intensity might be useful prognostic markers in the management of CD5+, B-cell CLL. The survival of CD5- patients was on the borderline of being significantly shorter than that of CD5+ patients. The majority of the CD5- cases were FMC7+, CD23-, had strong IgM fluorescence, and had splenomegaly.
APA, Harvard, Vancouver, ISO, and other styles
7

Geisler, CH, JK Larsen, NE Hansen, MM Hansen, BE Christensen, B. Lund, H. Nielsen, T. Plesner, K. Thorling, and E. Andersen. "Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia." Blood 78, no. 7 (October 1, 1991): 1795–802. http://dx.doi.org/10.1182/blood.v78.7.1795.bloodjournal7871795.

Full text
Abstract:
Blood mononuclear cells from 540 newly diagnosed, unselected patients with B-cell chronic lymphocytic leukemia (CLL) were examined by immunofluorescence flow cytometry for a panel of surface membrane markers, including IgM and IgD, the monoclonal antibodies anti-CD3, -5, -20, -21, -22, -FMC7, and, for the final 125 patients, anti-CD23. There were 503 CD5+ and 37 CD5- cases. In the CD5+ cases, the cells typically expressed IgM, IgD, CD20, CD21, CD22, and CD23. In univariate analysis, age, clinical stage, IgM-fluorescence intensity, CD23, and FMC7 had significant prognostic importance, with high IgM-fluorescence intensity, high FMC7, and low CD23 expression being associated with a short survival. There was no significant difference in survival between 351 cases expressing IgMD and 55 cases expressing IgM without IgD, or between kappa and lambda light chain monoclonal cases. CD20, CD21, and CD22 had no prognostic importance. In Cox multiple regression analyses, age, CD23, IgM-fluorescence intensity, and clinical stage (International Workshop System) had independent prognostic importance. Thus, besides clinical variables, CD23 and IgM intensity might be useful prognostic markers in the management of CD5+, B-cell CLL. The survival of CD5- patients was on the borderline of being significantly shorter than that of CD5+ patients. The majority of the CD5- cases were FMC7+, CD23-, had strong IgM fluorescence, and had splenomegaly.
APA, Harvard, Vancouver, ISO, and other styles
8

Escribano, Luis, Alberto Orfao, Jesús Villarrubia, Beatriz Díaz-Agustín, Carlos Cerveró, Agustín Rios, José L. Velasco, Juana Ciudad, José L. Navarro, and Jesús F. San Miguel. "Immunophenotypic Characterization of Human Bone Marrow Mast Cells. A Flow Cytometric Study of Normal and Pathological Bone Marrow Samples." Analytical Cellular Pathology 16, no. 3 (1998): 151–59. http://dx.doi.org/10.1155/1998/341340.

Full text
Abstract:
The goal of the present paper was to define the immunophenotype of bone marrow mast cells (BMMC) from healthy controls and patients with hematologic malignancies (HM) based on the use of multiple stainings with monoclonal antibodies analyzed by flow cytometry. Our results show that BMMC from both groups of individuals display a similar but heterogenous immunophenotype. The overall numbers of BMMC are higher in the HM group of individuals (p= 0.08). Three patterns of antigen expression were detected: (1) markers constantly positive in all cases analyzed (CD9, CD29, CD33, CD43, CD44, CD49d, CD49e, CD51, CD71, CD117, and FcεRI), (2) antigens that were constantly negative (CD1a, CD2, CD3, CD5, CD6, CD11a, CD14, CD15, CD16, CD19, CD20, CD21, CD23, CD25, CD30, CD34, CD38, CD41a, CD42b, CD65, CD66b, HLA-DR, and CD138), and (3) markers that were positive in a variable proportion of cases – CD11b (50%), CD11c (77%), CD13 (40%), CD18 (20%), CD22 (68%), CD35 (27%), CD40 (67%), CD54 (88%) and CD61 (40%). In addition, BMMC from all cases explored were CD45+, and this antigen was expressed at an intensity similar to that of mature granulocytes.In summary, our results show that BMMC from both healthy controls and HM patients display a relatively heterogenous immunophenotype. Interestingly, we have observed clear differences between the immunophenotype of BMMC and MC from other tissues. This could be due either to the heterogeneity of human MC according to their tissue localization or to the sensitivity of the method used for antigen detection.
APA, Harvard, Vancouver, ISO, and other styles
9

Weitzman, James, Monica Betancur, Laurent Boissel, Arthur P. Rabinowitz, and Hans Klingemann. "Variable Contribution of Different Monocloncal Antibodies to NK Cell-Mediated ADCC Against Primary CLL Cells." Blood 110, no. 11 (November 16, 2007): 4715. http://dx.doi.org/10.1182/blood.v110.11.4715.4715.

Full text
Abstract:
Abstract Chronic Lymphocytic Leukemia (CLL) is characterized by the expression of the B-cell antigens CD19, 20 and 22, along with CD5 and CD23. These antigens make the malignant cells an ideal target for monoclonal antibody (mAb) therapy. Although the mechanism of action of mAbs is complex and not fully understood, one well-described action is antibody-dependent cellular cytotoxicity (ADCC). Binding of mAb to its target surface antigen initiates cytotoxicity through the interaction of the Fc portion of the mAb with the Fc receptor (FcR) on natural killer (NK) cells. This triggers release of perforin and granzymes from NK cells, and subsequent killing of the target cells. This study’s objectives were to measure ADCC of 4 different mAbs against primary CLL cells, and determine if cytotoxicity is dependent on antigen density. Methods: Mononuclear cells from 16 patients with untreated CLL were separated by density gradient separation and served as targets. The antigen density for CD20, 22 and 23 of each patient sample was quantified by flow cytometry. Effector cells for ADCC were NK-92 cells that do not express FcR, and a high affinity Fc receptor-expressing NK-92 variant (NK92.26.5) that also expresses inhibitory receptors (i.e. KIR). A fluourochrome-based flow cytometric assay determined ADCC by subtracting NK-92 induced cytotoxicity from NK-92.26.5 induced killing. Monoclonal antibodies tested were Rituximab (anti-CD20, Biogen/IDEC), Veltuzumab (anti-CD20, Immunomedics), Epratuzumab (anti-CD22, Immunomedics), and Lumiliximab (anti-CD23, Biogen/IDEC). Results: Mean ADCC of the four antibodies tested against 16 primary CLL cells were: 46.5% for Rituximab; 43.4% for Veltuzumab; 5.8% for Epratuzumab; 8.8% for Lumiliximab. Cytotoxicity of NK-92 and NK-92.26.5 against CLL cells without antibody ranged from 2–6%. Mean antigen density on the 16 CLL patient specimens were: CD20: 27,900 (range: 10,000–56,100); CD22: 820 (600–1300); CD23: 9870 (2340–14,800). Conclusions: We have developed a reliable in vitro assay to measure ADCC of mAbs against CLL cells. Our results indicate that ADCC contributes to cytotoxcity of CLL in vitro, and suggest that the magnitude of ADCC depends upon the surface antigen targeted. Anti-CD20 antibodies had significantly greater ADCC than the anti-CD22 and CD23 antibodies. This pattern was consistent in all patient cells tested. A similar pattern was observed with the surface antigen density on CLL cells tested, suggesting a correlation between cell surface antigen density and ADCC. Our results also suggest that resistance of primary CLL cells toward NK-mediated killing can be overcome by monoclonal antibodies even in the presence of inhibitory KIR expression on NK cells.
APA, Harvard, Vancouver, ISO, and other styles
10

Kusakabe, Manabu, Guillermo Simkin, Justin Meskas, Chaoran Zhang, Daisuke Ennishi, Merrill Boyle, David W. Scott, et al. "Single Cell Mass Cytometry for Phenotypic Analysis of Diffuse Large B-Cell Lymphoma." Blood 124, no. 21 (December 6, 2014): 2976. http://dx.doi.org/10.1182/blood.v124.21.2976.2976.

Full text
Abstract:
Abstract Diffuse Large B-cell Lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin Lymphoma (NHL). Despite its improved outcome with R-CHOP chemotherapy, 40% of patients still suffer with relapsed or refractory disease. Further investigation is needed to understand the complexity of DLBCL. Time-of-flight mass cytometry (CyTOF) is a recently developed technology that combines traditional flow cytometry with mass spectrometry and supports analysis of up to 30-40 parameters simultaneously at the single cell level with minimal spectral overlap (Bendall et al, Science 2011). In this study, we sought to develop a CyTOF method for phenotypic analysis of DLBCL to obtain high resolution profiles of the malignant clone(s) represented in individual tumor samples and resolve any underlying population substructure that might be informative in understanding the clinical and biologic heterogeneity of this disease. We designed a two-tube assay for this study. Tube #1 contained 35 cell surface markers including CD45, CD19, CD20, CD22, CD79B, IgM, IgD, Ig Kappa, Ig Lambda, CD5, CD10, CD23, CD43, CD38, CD138, CD44, CD21, CD24, CD40, CD72, CD80, CD45RA, CD49D, CD49F, CD62L, CD25, CD27, CD30, CD127, CD184, CD194, CD200, CD34, HLA-DR, and CD3. Tube #2 contained 37 markers in total including 17 cell surface markers overlapping with Tube #1 plus an additional 20 intracellular markers (BCL2, BCL6, IRF4/MUM1, LMO2, MYC, MCL1, MEF2B, KAT3B/P300, CBP, FOXP1, RUNX1, Ikaros, EZH2, BMI1, NOTCH1, CARD11, IkBa, phospho-Rb, Ki67, and CyclinD2). Metal-conjugated antibodies were purchased from DVS Sciences or unconjugated antibodies labeled in-house using DVS MaxPar metal labeling kits. Data were acquired using a DVS CyTOF2 instrument. We examined both fresh and viably frozen single cell suspensions from diagnostic lymph node biopsy samples received for flow cytometric analysis at the BC Cancer Agency. We used SPADE (spanning-tree progression analysis of density-normalized events) for initial data analysis. We first performed preliminary validation studies including cross-comparison of mass cytometry (CyTOF2) vs. flow cytometry (BD Canto2) datasets and fresh vs. previously frozen cell suspension material. Although individual marker intensities using matched antibody clones were in general lower by CyTOF, eight-parameter surface staining results were qualitatively comparable between the two platforms. Also there were essentially no differences observed in CyTOF staining profiles between fresh and previously frozen samples. Preliminary clustering analysis of cell populations using SPADE revealed clear separation between normal and malignant B cell populations as well as apparent substructure to the malignant population in a subset of DLBCL samples. These findings suggest intratumoral heterogeneity can be resolved by high dimensional CyTOF analysis. Ongoing efforts will focus on determining if phenotypically defined subsets show enrichment for subclonal mutations. Disclosures No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "CD20 antibodies"

1

Eve, Heather E. "Lenalidomide and the new-generation anti-CD20 antibodies in mantle cell lymphoma." Thesis, Exeter and Plymouth Peninsula Medical School, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.573119.

Full text
Abstract:
Lenalidomide is a second-generation immunomodulatory drug with clinical activity in mantle cell lymphoma (MCL). In vitro work shows that lenalidomide enhances NK-mediated cytotoxicity against MCL yet the significance of this in vivo remains unproven. Since NK cells are key effectors of antibody-dependent cellular cytotoxicity (ADCC), there is a clear rationale for combining lenalidomide with monoclonal antibodies. However, one concern regarding this is the potential for lenalidomide to downregulate target antigen expression on malignant B Iymphocytes. This thesis presents phase II clinical trial data (EudraCT 2007-005472- 13) confirming the safety, efficacy and immunomodulatory activity of lenalidomide in relapsed/refractory MCL. Using a novel regimen, the benefit of lenalidomide as a low-dose maintenance agent is highlighted. Peripheral T and NK cells increased in responding patients with the NK rise preceded by an initial dip suggesting tumour infiltration. Peripheral Tregs were higher in MCL patients than controls and expanded further following lenalidomide. Bioloqically relevant changes were observed in plasma IL-12p40, IL-7, IL-10, adiponectin and MMP9. A significant correlation between gender and response suggested that female patients were more sensitive to lenalidomide than males. Finally, retrospective analysis of a historical cohort confirmed that thalidomide remains a valid treatment option for MCL patients unsuitable for lenalidomide. The new-generation anti-CD20 antibodies ofatumumab and GA 101 show superiority to rituximab in several B-cell malignancies although data regarding their efficacy in MCL is scarce. Cell culture work using the MCL cell line Granta519 showed ofatumumab was superior to rituximab at inducing complement-dependent cytotoxicity whilst GA 101 was superior to both rituximab and ofatumumab at inducing direct cytotoxicity and ADCC. Combining lenalidomide with these antibodies failed to have any additive cytotoxic effect. Lenalidomide induced significant CD20 downregulation on Granta519 cells. The alternative pan-B cell markers CD19 and, to a lesser extent, CD22 were also downregulated. Thus, if lenalidomide is to be combined with monoclonal antibodies in a clinical setting, sequential administration may be more beneficial than simultaneous administration.
APA, Harvard, Vancouver, ISO, and other styles
2

Walshe, Claire Anne. "Signalling cascades induced by type I and II anti-CD20 monoclonal antibodies." Thesis, University of Southampton, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.436973.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shan, Daming. "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies /." Thesis, Connect to this title online; UW restricted, 1998. http://hdl.handle.net/1773/5682.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

DIAS, CARLA R. de B. R. "Estudo comparativo da marcacao do anticorpo anti-CD20 com sup(188)Re." reponame:Repositório Institucional do IPEN, 2010. http://repositorio.ipen.br:8080/xmlui/handle/123456789/9502.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:27:22Z (GMT). No. of bitstreams: 0
Made available in DSpace on 2014-10-09T14:06:35Z (GMT). No. of bitstreams: 0
Tese (Doutoramento)
IPEN/T
Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
APA, Harvard, Vancouver, ISO, and other styles
5

Nolan, David Francis Luke. "The synergistic interaction between CD20 monoclonal antibodies and histone deacetylase inhibitors in B cell Non Hodgkin's Lymphoma." Thesis, University of Southampton, 2010. https://eprints.soton.ac.uk/162661/.

Full text
Abstract:
Recent improvements in molecular sub typing of Non Hodgkin’s lymphomas have resulted in targeted therapies becoming incorporated into treatment paradigms. The anti-CD20 monoclonal antibody, Rituximab, has resulted in dramatic improvements in survival for patients with B cell Non Hodgkin’s lymphoma. Histone deacetylase inhibitors are a novel class of anti cancer agents targeting epigenetic regulation. This thesis addresses the interaction between histone deacetylase inhibitors and anti-CD20 monoclonal antibodies, including Rituximab, both in vitro and in vivo. The initial approach identified synergistic induction of apoptosis in a number of B cell lines. In a Ramos xenograft model, combination treatment with suberoylanilide hydroxamic acid (SAHA) and Rituximab reduced tumour growth compared to either agent alone, without discernable toxicity. This effect appears specific to CD20 since monoclonal antibodies directed to other surface molecules (CD32b, CD22, CD37) did not exhibit cooperative effect. Analysis of apoptotic pathways demonstrated that PARP cleavage and caspase processing is significantly higher in cells receiving both treatments. Co-treatment of Ramos cells with the pan caspase inhibitor QVD-OPH abolished the synergy observed with CD20 monoclonal antibodies, suggesting that caspase processing is necessary for synergy. Treatment of Ramos cells stably transfected to overexpress Bcl-2 resulted in loss of synergy with Rituximab, but not with the type II CD20 mAb B1 (Tositumomab). Gene expression array analysis of Ramos cells was performed. Geneset enrichment analysis identified significant regulation of NFқB target genes in some genesets (Rituximab Vs control, p<0.001) with a number associated with apoptosis and B cell activation (Bcl2A1, LTA, CD69) which were confirmed using RT-Q-PCR. This novel combination elicits the induction of apoptosis in vitro, potentially through regulation of Bcl-2 family proteins and should be tested in a phase I/II clinical trial.
APA, Harvard, Vancouver, ISO, and other styles
6

Reslan, Lina. "Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia." Thesis, Lyon 1, 2010. http://www.theses.fr/2010LYO10346/document.

Full text
Abstract:
CD20 est une cible thérapeutique validée pour l’immunothérapie des néoplasmes lymphoïdesdes cellules B, incluant la Leucémie Lymphoïde Chronique (LLC). Nous avons comparé les effets de rituximab et de GA101 (nouvel anticorps anti-CD20) contre les cellules LLC fraiches in vitro. Le marquage avec Annexine V a démontré une induction de l’apoptose après l’exposition au rituximab et GA101.Contrairement au rituximab, GA101 induisait une réduction du potentiel transmembranaire mitochondrial, uneffet qui peut être partiellement inhibé par la cyclosporine A et qui est partiellement caspase-dépendant. GA101induisait aussi la production des espèces d’oxygènes réactives. L’analyse du niveau d’expression des protéinespro- et anti-apoptotiques après exposition aux anticorps a démontré une forte hétérogénéité entre les échantillons.Bax subissait une activation de conformation et une translocation mitochondriale suite à l’exposition aux anticorps d’une manière caspase-indépendante. GA101, mais pas rituximab, induisait le clivage des caspase-8, -9et -3. En transfectant les cellules LLC avec un siRNA ciblant Bcl-xL utilisant la sonoporation, nous avons trouvéque la réduction du niveau d’expression de Bcl-xL est associée à une augmentation de la sensibilité aux anticorps. Nos résultats suggèrent que les voies de signalisation apoptotiques diffèrent entre rituximab et GA101avec une implication de la voie mitochondriale avec le GA101. L’inhibition de Bcl-xL peut constituer une façon pour sensibiliser les cellules LLC aux effets apoptotiques des anticorps anti-CD20
CD20 is a validated target for the immunotherapy of B lymphoid neoplasms, including ChronicLymphocytic Leukemia (CLL). We compared the activities of rituximab and GA101 (novel anti-CD20 antibody)on fresh human CLL cells in vitro. AnnexinV staining demonstrated induction of apoptosis after exposure torituximab or GA101. Unlike rituximab, GA101 induced a reduction of the mitochondrial transmembranepotential, an effect which could be partially inhibited by cyclosporin A and which was partially caspasedependent.GA101 was also found to induce the production of Reactive Oxygen Species. Analysis of pro- andanti-apoptotic protein content after exposure to antibodies demonstrated a strong degree of heterogeneity between samples. Bax underwent conformational activation and mitochondrial translocation upon exposure toantibodies in a caspase-independent manner. GA101 but not rituximab induced cleavage of caspase-8, -9 and -3.By transfecting CLL cells with anti-Bcl-xL siRNA using a sonoporation method, we found that reduction of BclxLcontent was associated with increased sensitivity to these antibodies. Our results suggest that apoptoticsignalization pathways differ between rituximab and GA101 with a greater involvement of the mitochondrialpathway for GA101. Inhibition of Bcl-xL could constitute an approach to sensitize CLL cells to the apoptoticeffects of anti-CD20 antibodies
APA, Harvard, Vancouver, ISO, and other styles
7

Spasevska, Ivana. "The role of EGR-1 and calcium influx in the antitumor activity of anti-CD20 monoclonal antibodies." Thesis, Lyon, 2017. http://www.theses.fr/2017LYSE1304/document.

Full text
Abstract:
Les anticorps monoclonaux (AcM) anti-CD20 sont essentiels pour le traitement du lymphome non hodgkinien et de la leucémie lymphoïde chronique (LLC). Les AcM agissent soit en activant directement la signalisation apoptotique dans les cellules cibles, soit via le système immunitaire. Dans une étude préclinique, nous avons montré que le traitement avec AcM anti-CD20, rituximab et GA101, induit l'expression de la protéine early growth response 1 (EGR-1) (Dalle et al., 2011). EGR-1 est un facteur de transcription régulé par le calcium (Ca2+) et CD20 est impliqué dans la régulation du flux calcique transmembranaire. Nous avons donc étudié le rôle d'EGR-1 et du flux Ca2+ dans l'activité cytotoxique des AcM anti-CD20. Nous avons montré qu'EGR-1 est rapidement induit suite à l'exposition au rituximab et à GA101. La baisse de l'expression d'EGR-1 par shRNA a supprimé l'effet cytotoxique du GA101 à la fois in vitro et in vivo, indiquant qu'EGR-1 est requis pour la mort cellulaire médiée par CD20. De plus, la surexpression d'EGR-1 augmente la sensibilité au GA101 in vitro et in vivo. En outre, nos résultats indiquent que les AcM anti-CD20 induisent un flux Ca2+. Le blocage du flux Ca2+ par inhibiteurs de canaux calciques (ICC) a aboli l'induction d'EGR-1 ainsi que l'efficacité du GA101 in vivo et ex vivo dans des échantillons de LLC. Plus important, nos données indiquent que les patients recevant des ICC ont une moins bonne réponse au traitement par les AcM anti-CD20. En conclusion, nous avons identifié EGR-1 comme potentiel biomarqueur pour prédire la réponse à la thérapie anti-CD20 et démontré que les ICC ont un impact négatif sur l'efficacité des AcM anti-CD20 chez les patients
Anti-CD20 monoclonal antibodies (mAbs) are an essential component of the treatment of patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL). They mediate their antitumor effects by activating the immune system or by direct apoptotic signaling in target cells. In a previous preclinical study, we showed that treatment with anti-CD20 mAbs, rituximab and GA101, resulted in upregulated expression of early growth factor 1 (EGR-1) (Dalle et al. 2011). EGR-1 is a calcium (Ca2+) regulated transcription factor and CD20 is hypothesized to regulate transmembrane Ca2+ flux. Therefore, we aimed to assess the role of EGR-1 and Ca2+ flux in the cytotoxic activity of anti-CD20 mAbs. We have shown that EGR-1 expression is rapidly upregulated in CD20+ cells following rituximab and GA101 exposure. Decreasing EGR-1 expression by shRNA abolishes the direct cytotoxic effect of GA101 both in vitro and in vivo, indicating that EGR-1 is required for CD20-mediated cell death. Additionally, the overexpression of EGR-1 enhances the cytotoxic activity of GA101 both in vitro and in vivo. Furthermore, our results indicate that anti-CD20 mAbs induce calcium influx. Blocking the Ca2+ flux with calcium channel blockers (CCB) abolishes EGR-1 induction and impaires the GA101 efficacy in vivo and ex vivo in CLL blood samples. More importantly, our data indicate that patients receiving CCBs and anti-CD20 therapy have worst progression free survival and overall survival. In conclusion we have identified EGR-1 as a potential biomarker to predict response to anti-CD20 therapy. We demonstrated that co-treatement with CCBs negatively impacts the outcome of patients receiving anti-CD20 mAbs
APA, Harvard, Vancouver, ISO, and other styles
8

AKANJI, AKINKUNMI G. "Estudo de marcação com iodo-131 de anticorpo monoclonal anti-CD20 usado na terapia de linfoma nao-hodgkin." reponame:Repositório Institucional do IPEN, 2006. http://repositorio.ipen.br:8080/xmlui/handle/123456789/11488.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:52:27Z (GMT). No. of bitstreams: 0
Made available in DSpace on 2014-10-09T14:01:38Z (GMT). No. of bitstreams: 0
Dissertação (Mestrado)
IPEN/D
Instituto de Pesquisas Energeticas e Nucleares - IPEN/CNEN-SP
APA, Harvard, Vancouver, ISO, and other styles
9

Nishida, Michio. "Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions." Kyoto University, 2008. http://hdl.handle.net/2433/124332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

AKANJI, AKINKUNMI G. "Estudo de conjugação do anticorpo anti-CD20 para marcação com radionuclídeos metálicos ou lantanídeos." reponame:Repositório Institucional do IPEN, 2013. http://repositorio.ipen.br:8080/xmlui/handle/123456789/28021.

Full text
Abstract:
Submitted by Pedro Silva Filho (pfsilva@ipen.br) on 2017-11-17T17:17:04Z No. of bitstreams: 0
Made available in DSpace on 2017-11-17T17:17:04Z (GMT). No. of bitstreams: 0
Linfomas são cânceres que se iniciam a partir da transformação maligna de um linfócito no sistema linfático. Os linfomas são divididos em duas categorias principais: os linfomas de Hodgkin e todos os outros linfomas, denominados linfomas não-Hodgkin (LNH). Os pacientes com LNH são comumente tratados com radioterapia apenas ou combinada com quimioterapia utilizando-se de anticorpo monoclonal anti-CD20, principalmente o rituximab (MabThera®). O uso de anticorpos monoclonais (Acm) conjugados à quelantes bifuncionais radiomarcados com radionuclídeos metálicos ou lantanídeos é uma realidade de tratamento para portadores de LNH pelo princípio de radioimunoterapia (RIT). Este estudo concentrou-se nas condições de conjugação do anticorpo monoclonal rituximab (MabThera®) com grupamentos quelantes bifuncionais DOTA e DTPA. Na marcação dos Acm conjugados com lutécio-177, foram estudadas as condições de pré-purificação do Acm, condições de conjugação, determinação de número de quelantes acoplados à molécula do anticorpo, purificação do anticorpo conjugado, radiomarcação do anticorpo conjugado, com lutécio-177, purificação do anticorpo marcado, a ligação específica in vitro dos compostos marcados às células Raji, e distribuição biológica em camundongos BALB/c sadios. As três metodologias empregadas na pré-purificação do anticorpo (diálise, cromatografia de exclusão molecular com coluna Sephadex G-50 e ultrafiltração) demonstram-se eficientes e proporcionaram recuperação da amostra superior a 90%. A metodologia de ultrafiltração foi considerada a mais simples e prática, podendo ser aplicada a procedimentos rotineiros de produção de radiofármacos. Além disso, proporcionou a recuperação final de amostra de 97% em microlitros. Nas conjugações do anticorpo com os quelantes DOTA e DTPA em razões molares diferentes do Acm:quelante, observou-se número de grupamentos quelantes acoplados à molécula do Acm proporcional à razão molar estudada. Quando foi avaliada a influência de condições diferentes de conjugação no número de quelantes acoplados à molécula do Acm, não foram observadas diferenças significativas, com resultados de pureza radioquímica (PR) inferior a 80% em todas as condições estudadas. Na comparação de métodos de purificação do Acm conjugado, a abordagem inédita apresentada neste estudo, na qual a cromatografia de exclusão molecular foi combinada com a ultrafiltração resultou em maior eficiência na purificação e preservação da estrutura do anticorpo. Nos estudos de radiomarcação do anticorpo conjugado com DOTA e DTPA, os imunoconjugados de DTPA apresentaram, de forma geral, maior eficiência de marcação com resultados reprodutíveis quando comparados com os imunoconjugados de DOTA, considerando-se as diferentes razões molares utilizadas. As metodologias cromatográficas empregadas no controle de pureza radioquímica do composto radiomarcado proporcionaram a discriminação das diferentes espécies radioquímicas no meio de marcação. A metodologia de purificação do composto conjugado e radiomarcado utilizada proporcionou a obtenção de compostos com alta pureza radioquímica, 97,4±1,3% (DOTA 1:50) e 98,7±0,2% (DTPA 1:50). Nos estudos de ligação específica às células tumorais Raji, o anticorpo conjugado com quelante DTPA nas razões molares de 1:50 e 1:20 apresentaram perfil semelhante de ligação, com aumento da porcentagem de ligação específica proporcional à concentração celular, enquanto que o imunoconjugado na razão molar de 1:10 apresentou alta porcentagem de ligação não específica. Os resultados obtidos nos estudos de biodistribuição in vivo do anticorpo conjugado e radiomarcado nem sempre se mostraram compatíveis com a biodistribuição de anticorpos radiomarcados íntegros. No caso do quelante DOTA, o imunoconjugado obtido a partir da razão molar 1:20, apresentou melhores características de biodistribuição. No caso do quelante DTPA, a razão molar utilizada pareceu refletir diretamente no clareamento sanguíneo do anticorpo e todas as razões molares utilizadas apresentaram instabilidade in vivo.
Tese (Doutorado em Tecnologia Nuclear)
IPEN/T
Instituto de Pesquisas Energéticas e Nucleares - IPEN-CNEN/SP
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "CD20 antibodies"

1

Cho, William Chi Shing. Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal. Elsevier Science & Technology Books, 2023.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dörner, Thomas, and Peter E. Lipsky. Cellular side of acquired immunity (B cells). Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0050.

Full text
Abstract:
B cells have gained interest in rheumatoid arthritis (RA) beyond being the precursors of antibody-producing plasma cells since they are also a broader component of the adaptive immune system. They are capable of functioning as antigen-presenting cells for T-cell activation and can produce an array of cytokines. Disturbances of peripheral B-cell homeostasis together with the formation of ectopic lymphoid neogenesis within the inflamed synovium appears to be a characteristic of patients with RA. Enhanced generation of memory B cells and autoreactive plasma cells producing IgM-RF and ACPA-IgG antibodies together with formation of immune complexes contribute to the maintenance of RA, whereas treatment with B-cell-directed anti-CD20 therapy provides clinical benefit.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "CD20 antibodies"

1

Lindorfer, Margaret A., Joost M. Bakker, Paul W. H. I. Parren, and Ronald P. Taylor. "Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity." In Handbook of Therapeutic Antibodies, 1733–74. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch63.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Klein, Christian, Marina Bacac, Pablo Umaña, and Michael Wenger. "Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma." In Handbook of Therapeutic Antibodies, 1695–732. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch62.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jacene, Heather A., and Richard L. Wahl. "Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, “Bexxar”)." In Therapeutic Nuclear Medicine, 505–25. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/174_2013_943.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Newton, Dianne L., Luke H. Stockwin, and Susanna M. Rybak. "Anti-CD22 Onconase: Preparation and Characterization." In Therapeutic Antibodies, 425–43. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-554-1_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

van de Donk, Niels W. C. J., and Eugen Dhimolea. "Brentuximab Vedotin (Adcetris®) for the Treatment of CD30-Positive Hematologic Malignancies." In Handbook of Therapeutic Antibodies, 1417–44. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Elluru, Sri Ramulu, Srini V. Kaveri, and Jagadeesh Bayry. "Regulation of Human Dendritic Cell Functions by Natural Anti-CD40 Antibodies." In Methods in Molecular Biology, 47–54. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0669-7_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Reinhold, D., T. Kähne, M. Täger, U. Lendeckel, F. Bühling, U. Bank, S. Wrenger, J. Faust, K. Neubert, and S. Ansorge. "The Effect of Anti-CD26 Antibodies on DNA Synthesis and Cytokine Production (IL-2, IL-10 and IFN-γ) Depends on Enzymatic Activity of DP IV/CD26." In Advances in Experimental Medicine and Biology, 149–55. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4757-9613-1_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Turco, Maria Caterina, Mario De Felice, Soo Young Yang, Soldano Ferrone, and Salvatore Venuta. "Differential Modulation by Anti-HLA Class I Monoclonal Antibodies of T Cell Proliferation Induced via CD2 and CD3 Pathways." In Immunobiology of HLA, 147–50. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-662-39946-0_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ferrone, S., M. De Felice, M. C. Turco, L. Corbo, and S. Venuta. "Effect of Anti-HLA Class I Monoclonal Antibodies on the Proliferation of T Cells Induced by PHA-P. Comparison with the Effect on T Cell Activation via the CD2 and CD3 Pathways." In MHC + X, 100–106. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-74026-8_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bernard, Alain, Philippe Brottier, Eric Georget, Virginia Lepage, and Laurence Boumsell. "The Epitopic Dissection of the CD2 Defined Molecule: Relationship of the Second Workshop Antibodies in Terms of Reactivities with Leukocytes, Rosette Blocking Properties, Induction of Positive Modulation of the Molecule, and Triggering T Cell Activation." In Leukocyte Typing II, 53–66. New York, NY: Springer New York, 1986. http://dx.doi.org/10.1007/978-1-4613-8587-5_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "CD20 antibodies"

1

Tent, Michiel. "Chronic active MS lesions respond poorly to anti-CD20 antibodies." In ECTRIMS Congress 2022, edited by Hans-Peter Hartung. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/45da9aa4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Moskalets, O. V. "The incidence of anti-rituximab antibodies in patients with chronic lymphocytic leukemia." In Global science. Development and novelty. L-Journal, 2020. http://dx.doi.org/10.18411/gsdn-25-12-2020-05.

Full text
Abstract:
The aim of this study was to investigate the incidence of antibodies to rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, in patients with chronic lymphocytic leukemia. Serum concentrations of anti-rituximab antibodies were determined in patients with B-chronic lymphocytic leukemia (newly diagnosed and resistant / recurrent forms, previously treated by rituximab) and healthy controls. Results: none of the patients with newly diagnosed disease have antibodies to rituximab. Positive results were recorded in 8 (33%) patients who received rituximab earlier.
APA, Harvard, Vancouver, ISO, and other styles
3

Xu, Wei, Johannes Sam, Mario Perro, John Challier, Christina Claus, Stanford Chen, Claudia Ferrara Koller, et al. "Abstract 957: Design of CD19-4-1BBL, a novel CD19-targeted 4-1BB ligand for combination therapy with CD20 T-cell bispecific antibodies and CD20 antibodies." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-957.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Moskalets, O. V. "Anti-rituximab antibodies in refractory / relapsing cases of chronic lymphocytic leukemia." In General question of world science. L-Journal, 2020. http://dx.doi.org/10.18411/gq-30-11-2020-02.

Full text
Abstract:
Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, is widley used for treatment of lymphomas, rheumatologic diseases and other – 8 – General question of world science disorders. It is known that many monoclonal antibodies such as rituximab can elicit anti-drug antibodies, which may interfere with therapeutic response. The aim of this study was to investigate the incidence of antibodies to rituximab in patients with chronic lymphocytic leukemia. Serum concentrations of anti-rituximab antibodies was determined in blood serum of patients with B-chronic lymphocytic leukemia (newly diagnosed and resistant / recurrent forms, previously treated by rituximab) and healthy controls. Results: none of the patients with newly diagnosed disease have antibodies to rituximab. Positive results were recorded in 8 (33%) patients who received rituximab earlier
APA, Harvard, Vancouver, ISO, and other styles
5

Gupta, Pankaj, Edmund A. Rossi, David M. Goldenberg, and Chien-Hsing Chang. "Abstract 4572: Heterodimerization of CD74 and CD20 by two hexavalent, bispecific, anti-CD20/CD74 antibodies leads to potent cytotoxicity in mantle cell lymphoma." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4572.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Spasevska, Ivana, Jade Villé, Kamel Chettab, Eva-Laure Matera, and Charles Dumontet. "Abstract 4594: Induction of apoptosis by anti-CD20 antibodies requires the induction of EGR-1 and calcium influx." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pyrzynska, Beata, Abdessamad Zerrouqi, Michal Dwojak, Giulia Morlino, Piotr Zapala, Nina Miazek, Agnieszka Zagozdzon, et al. "Abstract B17: FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; October 1-4, 2017; Boston, MA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/2326-6074.tumimm17-b17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zerrouqi, Abdessamad, Beata Pyrzynska, Michal Dwojak, Nina Miazek, Piotr Zapala, Jakub Golab, and Magdalena Winiarska. "Abstract B27: B-cell lymphoma response to anti-CD20 antibodies based therapies is tightly modulated by FOXO1-mediated MS4A1 gene transcription." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; October 1-4, 2017; Boston, MA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/2326-6074.tumimm17-b27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zerrouqi, Abdessamad, Nina Miazek-Zapala, Anna Torun, Piotr Zapala, Jakub Golab, Magdalena Winiarska, and Beata Pyrzynska. "Abstract LB-261: Salinomycin expands the cytotoxicity of both anti-CD20 monoclonal antibodies and natural killer cells towards non-Hodgkin lymphomas." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-lb-261.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zerrouqi, Abdessamad, Nina Miazek-Zapala, Anna Torun, Piotr Zapala, Jakub Golab, Magdalena Winiarska, and Beata Pyrzynska. "Abstract LB-261: Salinomycin expands the cytotoxicity of both anti-CD20 monoclonal antibodies and natural killer cells towards non-Hodgkin lymphomas." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-lb-261.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "CD20 antibodies"

1

Wu, Xin. The efficacy and safety of anti-CD20 antibody treatments in relapsing multiple sclerosis: a systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0075.

Full text
Abstract:
Review question / Objective: The objectives of this systematic review were to evaluate the efficacy and safety of the three existing anti-CD20 antibodies for the treatment of relapsing multiple sclerosis and to aid clinicians in choosing medications. Eligibility criteria: We set the inclusion criteria as follows: (1) study type: RCT; (2) language restriction: only available in English; (3) participants: patients ≥18 years of age diagnosed with relapsing MS, whether with a relapsing–remitting course or a secondary progressive course; (4) intervention: anti-CD20 antibody treatments including ocrelizumab, ofatumumab, rituximab, and corresponding control including placebo and active treatments; (5) outcomes: clinical outcomes including annualized rate of relapse (ARR), the number of patients free of relapse, and the number of patients with confirmed disease progression (CDP); magnetic resonance imaging(MRI) outcomes including gadolinium-enhancing lesion change in T1, change in the volume of lesions on T2, the number of patients with no new or newly enlarged lesions in T2 and the brain volume change (BVC); safety outcomes including adverse events (AEs) and serious adverse events (SAEs). Included RCTs were not requested to supply all the outcomes mentioned above. We set the exclusion criteria as follows: (1) study type: retrospective studies, cohort studies, case reviews and case reports; (2) patients diagnosed with primary progressive MS.
APA, Harvard, Vancouver, ISO, and other styles
2

Lin, Zhijuan, Xing Chen, Long Liu, Zhifeng Li, and Bing Xu. Chemo-Free Treatments in Relapsed and/or Refractory Follicular Lymphoma: A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0111.

Full text
Abstract:
Review question / Objective: FL is the most common indolent B cell lymphoma worldwide and patients with FL always have long term survival. However, advanced FL remains incurable and there is no universal agreement on optimal regimen to manage relapsed FL. Condition being studied: The efficacy of chemo-free regimens, including CD20 antibodies and targeted agents, in relapsed and/or refractory Follicular lymphoma. Information sources: We used the MEDLINE, Embase, and Cochrane Library databases to search the RCTs met our selection criteria. We also searched clinicalTrials.gov and the international clinical trial registry platform for completed and ongoing trials. In addition, we searched abstracts that published on American Society of Hematology (ASH), The European Hematology Association (EHA) or American Society of Clinical Oncology (ASCO) meetings.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'CD20 antibodies' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography